34318620|t|Humoral response to neurofilaments and dipeptide repeats in ALS progression.
34318620|a|OBJECTIVE: To appraise the utility as biomarkers of blood antibodies and immune complexes to neurofilaments and dipeptide repeat proteins, the products of translation of the most common genetic mutation in amyotrophic lateral sclerosis (ALS). METHODS: Antibodies and immune complexes against neurofilament light, medium, heavy chains as well as poly-(GP)-(GR) dipeptide repeats were measured in blood samples from the ALS Biomarkers (n = 107) and the phenotype-genotype biomarker (n = 129) studies and in 140 healthy controls. Target analyte levels were studied longitudinally in 37 ALS cases. Participants were stratified according to the rate of disease progression estimated before and after baseline and C9orf72 genetic status. Survival and longitudinal analyses were undertaken with reference to matched neurofilament protein expression. RESULTS: Compared to healthy controls, total neurofilament proteins and antibodies, neurofilament light immune complexes (p < 0.0001), and neurofilament heavy antibodies (p = 0.0061) were significantly elevated in ALS, patients with faster progressing disease (p < 0.0001) and in ALS cases with a C9orf72 mutation (p < 0.0003). Blood neurofilament light protein discriminated better ALS from healthy controls (AUC: 0.92; p < 0.0001) and faster from slower progressing ALS (AUC: 0.86; p < 0.0001) compared to heavy-chain antibodies and light-chain immune complexes (AUC: 0.79; p < 0.0001 and AUC: 0.74; p < 0.0001). Lower neurofilament heavy antibodies were associated with longer survival (Log-rank Chi-square: 7.39; p = 0.0065). Increasing levels of antibodies and immune complexes between time points were observed in faster progressing ALS. CONCLUSIONS: We report a distinctive humoral response characterized by raising antibodies against neurofilaments and dipeptide repeats in faster progressing and C9orf72 genetic mutation carriers ALS patients. We confirm the significance of plasma neurofilament proteins in the clinical stratification of ALS.
34318620	39	48	dipeptide	Chemical	MESH:D004151
34318620	60	63	ALS	Disease	MESH:D000690
34318620	283	312	amyotrophic lateral sclerosis	Disease	MESH:D000690
34318620	314	317	ALS	Disease	MESH:D000690
34318620	422	432	poly-(GP)-	Chemical	-
34318620	437	446	dipeptide	Chemical	MESH:D004151
34318620	495	498	ALS	Disease	MESH:D000690
34318620	660	663	ALS	Disease	MESH:D000690
34318620	785	792	C9orf72	Gene	203228
34318620	1134	1137	ALS	Disease	MESH:D000690
34318620	1139	1147	patients	Species	9606
34318620	1200	1203	ALS	Disease	MESH:D000690
34318620	1217	1224	C9orf72	Gene	203228
34318620	1303	1306	ALS	Disease	MESH:D000690
34318620	1388	1391	ALS	Disease	MESH:D000690
34318620	1759	1762	ALS	Disease	MESH:D000690
34318620	1881	1890	dipeptide	Chemical	MESH:D004151
34318620	1925	1932	C9orf72	Gene	203228
34318620	1959	1962	ALS	Disease	MESH:D000690
34318620	1963	1971	patients	Species	9606
34318620	2068	2071	ALS	Disease	MESH:D000690
34318620	Association	MESH:D000690	203228
34318620	Association	MESH:D004151	MESH:D000690

